Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Lirentelimab in H1 Antihistamine-Refractory Chronic Spontaneous Urticaria
2022-001847-26Phase 2Terminated
- Sponsor
- Allakos Inc.
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic idiopathic urticaria (CIU) comparing Lirentelimab with Placebo (2 arms). Primary endpoint: Change in UAS7 at Week 12. Started Nov 2022; status: terminated.
02
Drugs
lirentelimab
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on 2022-001847-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001847-26.